Condition Directory

Breast Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Breast Cancer. Browse Breast Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 4, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 3, 2026, 8:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1486

Shown on this page

Current sort

How Breast Cancer studies are organized in the registry

Breast cancer listings are usually subtype-specific: receptor status appears directly in titles and condition fields, so subtype terms narrow results far better than stage words alone. Many studies also restrict to either early-stage or metastatic settings, which is visible in the title or eligibility section of the official record.

Terms that often appear in related listings

triple-negative HER2-positive hormone receptor-positive metastatic breast cancer

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 769–780 of 1,486 matching trials for Breast Cancer.

Indexed local directory records.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Open in full search

Conditions: Metastatic Triple Negative Breast Cancers
Interventions: Sacituzumab tirumotecan; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Early-stage Breast Cancer
Interventions: Radiation Therapy; Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Cancer, Female Breast Carcinoma
Interventions: Palbociclib, anastrozole; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Inflammatory Breast Cancer (IBC)
Interventions: Cyclophosphamide, Doxorubicin, Paclitaxel, Ruxolitinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Boston, Massachusetts • Rochester, Minnesota • Durham, North Carolina + 1 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Endometrial Carcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions: Aerobic Exercise, Biospecimen Collection, Dietary Intervention, Discussion, Goal Setting, Internet-Based Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Resistance Training, Smartphone Application-based Intervention, Supportive Care, Tailored Intervention; Other · Procedure · Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 40 Years to 69 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Early-stage Breast Cancer, Invasive Ductal Carcinoma of Female Breast
Interventions: Partial Breast Irradiation (PBI); Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Cancer, Colorectal Cancer, Food Deprivation, Food Habits, Food Selection, Gynecologic Cancer, Hematologic Cancer, Lung Cancer, Melanoma, Nutrition Poor, Nutritional Deficiency, Prostate Cancer, Skin Cancer
Interventions: MyCarePulse and ASCENT PN; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Advanced Solid Tumor, Breast Cancer, Homologous Recombination Deficiency, Metastatic Solid Tumor, Ovarian Cancer, Pancreas Cancer, Prostate Cancer
Interventions: MOMA-313, Olaparib; Drug
Lead sponsor: MOMA Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Goodyear, Arizona • La Jolla, California • San Francisco, California + 8 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Naxitamab, Universal Donor Expanded TGF-beta-imprinted NK Cells; Procedure · Drug · Biological
Lead sponsor: Margaret Gatti-Mays; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim; Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Baltimore, Maryland • Seattle, Washington • Madison, Wisconsin

Conditions: Breast Cancer Female, Early-stage Breast Cancer
Interventions: Intraoperative Radiation Therapy, Lumpectomy; Radiation · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 55 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2033
U.S. locations: 1
States / cities: Macon, Georgia

Conditions: HER2-positive Breast Cancer
Interventions: T-DM1, placebo, tucatinib; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 321
States / cities: Mobile, Alabama • Gilbert, Arizona • Goodyear, Arizona + 180 more

About this Breast Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Breast Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Breast Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Breast Cancer clinical trials

How Breast Cancer studies are organized in the registry

Filter and sort this condition

Stored official records

Sac-TMT for Active TNBC Brain Metastases

Outcomes and Cosmesis With Whole Breast Irradiation and Boost

Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial

Radiation After No Axillary Nodal Sampling

The Florida ASCENT Study

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

IORT-Breast at Medical Center Navicent Health

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

About this Breast Cancer clinical trials directory page